2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2775

Conductive Hearing Loss Is Common in Ankylosing Spondylitis
Abstract Number: 2776

Comparability of Patients Classified As Non-Radiographic Axial Spondyloarthritis By the Imaging Vs Clinical Arms of the ASAS Criteria
Abstract Number: 2777

Is There a Difference in Clinical Features and Burden of Disease in Patients with Axial Spondyloarthritis with and without Extra-Articular Manifestations?
Abstract Number: 2778

Is There Any Gender Specific Difference in Discriminative Value of Inflammatory Back Pain Criteria?
Abstract Number: 2779

Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2780

A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Abstract Number: 2781

Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
Abstract Number: 2782

Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Abstract Number: 2783

Human Mesenchymal Stem Cells from Different Tissues Exert Distinct Therapeutic Effect on Systemic Lupus Erythematosus
Abstract Number: 2784

Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice
Abstract Number: 2785

Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)
Abstract Number: 2786

The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Abstract Number: 2787

Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity
Abstract Number: 2788

Suppression of IL-1 Signaling Ameliorates Dermatitis in a Murine Model of Systemic Lupus Erythematosus
Abstract Number: 2789

Novel Glucocorticoid Prodrug Effectively Attenuates Late Stage Lupus Nephritis with Improved Safety Profile

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].